Deep sleep declines linearly at 2% per decade. By 60, you've lost a third of your slow-wave sleep. By 90, it's functionally gone. Now extrapolate to 200. You've built a body that won't age — congratulations — and paired it with a brain that hasn't been cleaned in a century.

This isn't metaphor. Your brain has a literal sewage system: the glymphatic network, a fluid-transport pathway that flushes amyloid-beta, tau, and metabolic waste through perivascular channels. It runs almost exclusively during deep sleep, driven by norepinephrine oscillations from the locus coeruleus that generate slow vasomotion. When slow-wave sleep degrades, glymphatic flow drops. The waste accumulates. The plaques build. The neurodegeneration begins — not because your neurons failed, but because they were never cleaned.

We know this isn't just correlation. Locus coeruleus degeneration precedes Alzheimer's by decades. Sleep fragmentation predicts amyloid deposition years before cognitive symptoms. Every 10-year error in sleep-derived biological age corresponds to 29% higher mortality. The brain's cleaning schedule isn't a lifestyle factor — it's a survival mechanism, and it fails on a clock.

Here's what disturbs me about the longevity field: we have drugs for everything except this. Rapamycin inhibits mTOR. Senolytics clear zombie cells. Metformin mimics caloric restriction. NAD+ precursors boost mitochondrial function. None of them restore slow-wave sleep architecture. Not one. The hypothalamic circuits that generate sleep's deep oscillations — the ventrolateral preoptic area, the orexin system, the thalamic reticular nucleus — age through mechanisms that are completely orthogonal to the pathways longevity pharmacology targets.

You can clear every senescent cell in a 200-year-old brain. You can flood it with NAD+. You can suppress mTOR until the cellular recycling machinery hums like it's 25. And that brain will still drown in its own metabolic waste every night because it can't generate the slow waves needed to flush it.

The irony is that we actually have a pharmacological lead: dual orexin receptor antagonists (DORAs) like suvorexant, originally developed for insomnia, are showing neuroprotective effects and reduced amyloid accumulation in early trials. They work by modulating the exact wake-promoting circuits that degrade with age. But funding for sleep-as-longevity-intervention is a rounding error compared to what we pour into senolytics and reprogramming.

The longest-lived humans offer a clue. Centenarian studies show that maintenance of slow-wave sleep — both quantity and delta power — correlates with survival independently of every other biomarker. These aren't people with better mitochondria or fewer senescent cells. They're people whose brains still clean themselves at night.

We're engineering a 200-year lifespan and ignoring the fact that the brain's maintenance window closes decades before the body fails. If you're working on hypothalamic rejuvenation, orexin circuit restoration, or glymphatic enhancement — you're not working on sleep. You're working on the rate-limiting step of human longevity, and almost nobody knows it.